| Dr Neil Mcdevitt Skemp, MD | |
|
3366 Oakdale Ave N Ste 303, Robbinsdale, MN 55422-2977 | |
| (763) 520-7700 | |
| (833) 905-2110 |
| Full Name | Dr Neil Mcdevitt Skemp |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 27 Years |
| Location | 3366 Oakdale Ave N Ste 303, Robbinsdale, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477504876 | NPI | - | NPPES |
| 1477504876 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 45619 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ridgeview Medical Center | Waconia, MN | Hospital |
| North Memorial Health | Robbinsdale, MN | Hospital |
| Maple Grove Hospital | Maple grove, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Minnesota Urology Pa | 0840183984 | 67 |
News Archive
SpineAlign Medical, Inc. announced today that it has enrolled its initial patient in the European Observational Registry for the VerteLift System, an observation study to further assess the ability of the VerteLift System to treat the pain and dysfunction associated with osteoporotic vertebral compression fractures (VCF), while providing clinically measurable height restoration based upon previous European experience and analysis.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
Allscripts today announced that Sharp HealthCare has selected the Allscripts Community Record, provided in partnership with dbMotion, to deliver end-to-end connectivity across the health system. Using the Allscripts solution, Sharp's caregivers and those in affiliated physician practices will have shared access to a single, unified patient record, bridging gaps that often exist between hospital-based and office-based care.
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.
› Verified 1 days ago
| Entity Name | Minnesota Urology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912971912 PECOS PAC ID: 0840183984 Enrollment ID: O20040204000003 |
News Archive
SpineAlign Medical, Inc. announced today that it has enrolled its initial patient in the European Observational Registry for the VerteLift System, an observation study to further assess the ability of the VerteLift System to treat the pain and dysfunction associated with osteoporotic vertebral compression fractures (VCF), while providing clinically measurable height restoration based upon previous European experience and analysis.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
Allscripts today announced that Sharp HealthCare has selected the Allscripts Community Record, provided in partnership with dbMotion, to deliver end-to-end connectivity across the health system. Using the Allscripts solution, Sharp's caregivers and those in affiliated physician practices will have shared access to a single, unified patient record, bridging gaps that often exist between hospital-based and office-based care.
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.
› Verified 1 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
SpineAlign Medical, Inc. announced today that it has enrolled its initial patient in the European Observational Registry for the VerteLift System, an observation study to further assess the ability of the VerteLift System to treat the pain and dysfunction associated with osteoporotic vertebral compression fractures (VCF), while providing clinically measurable height restoration based upon previous European experience and analysis.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
Allscripts today announced that Sharp HealthCare has selected the Allscripts Community Record, provided in partnership with dbMotion, to deliver end-to-end connectivity across the health system. Using the Allscripts solution, Sharp's caregivers and those in affiliated physician practices will have shared access to a single, unified patient record, bridging gaps that often exist between hospital-based and office-based care.
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Neil Mcdevitt Skemp, MD 3001 Metro Dr Ste 460, Bloomington, MN 55425-1548 Ph: (651) 999-7022 | Dr Neil Mcdevitt Skemp, MD 3366 Oakdale Ave N Ste 303, Robbinsdale, MN 55422-2977 Ph: (763) 520-7700 |
News Archive
SpineAlign Medical, Inc. announced today that it has enrolled its initial patient in the European Observational Registry for the VerteLift System, an observation study to further assess the ability of the VerteLift System to treat the pain and dysfunction associated with osteoporotic vertebral compression fractures (VCF), while providing clinically measurable height restoration based upon previous European experience and analysis.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
Allscripts today announced that Sharp HealthCare has selected the Allscripts Community Record, provided in partnership with dbMotion, to deliver end-to-end connectivity across the health system. Using the Allscripts solution, Sharp's caregivers and those in affiliated physician practices will have shared access to a single, unified patient record, bridging gaps that often exist between hospital-based and office-based care.
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.
› Verified 1 days ago
Dr. Joseph Charles Cerny Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3366 Oakdale Ave N, Suite 409, Robbinsdale, MN 55422 Phone: 763-520-7700 Fax: 763-520-7776 |